The study concluded that the vaccine, engineered to target a broad spectrum of infectious diseases including COVID-19, failed to generate a significant increase in neutralising antibody levels among the approximately 30 participants involved in the trial.

Despite the modest clinical efficacy, the research team emphasised that the project represents a major methodological milestone, marking the first time a vaccine fully constructed by AI-driven algorithms has reached human testing. The active component of the vaccine was synthesised using genetic data from multiple coronaviruses—specifically those responsible for COVID-19, SARS, and MERS—with the goal of predicting future viral mutations and eliminating the need for frequent booster updates.

Furthermore, the trial recorded no serious adverse side effects among the participants, confirming a strong safety profile. Researchers note that this safety data, combined with the groundbreaking computational framework, establishes a solid foundation for further clinical testing and optimisation in larger subsequent studies.